Core Laboratories (NYSE: CLB) director receives 7,895 RSUs, 8,069 shares vest
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Core Laboratories Inc. director Robert F. Martinovich reported equity-based compensation activity. He received a grant of 7,895 Restricted Shares that will vest after a one-year vesting period ending on April 1, 2027, subject to the terms of issuance and any deferral election.
Separately, 8,069 Restricted Shares vested at the end of a prior one-year vesting period on April 1, 2026 and were exercised into 8,069 shares of Common Stock, which he now holds directly. The filing shows only awards and an option-style conversion of restricted equity into common stock, with no open-market purchases or sales.
Positive
- None.
Negative
- None.
Insider Trade Summary
8,069 shares exercised/converted
Mixed
3 txns
Insider
MARTINOVICH ROBERT F
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Restricted Shares | 7,895 | $0.00 | -- |
| Exercise | Restricted Shares | 8,069 | $0.00 | -- |
| Exercise | Common Stock | 8,069 | $0.00 | -- |
Holdings After Transaction:
Restricted Shares — 7,895 shares (Direct);
Common Stock — 8,069 shares (Direct)
Footnotes (1)
- The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period on April 1, 2027, subject to the terms of issuance. Such shares remain subject to a deferral election by the Reporting Person in accordance with Treasury Regulation 1.409A-2, and the vested portion thereof will be distributed as shares of common stock following the Reporting Person's separation of service from the Board. The Restricted Shares vested at the end of a one-year vesting period ending April 1, 2026.
Key Figures
Restricted Shares granted: 7,895 shares
New grant vesting date: April 1, 2027
Restricted Shares vested: 8,069 shares
+3 more
6 metrics
Restricted Shares granted
7,895 shares
Equity award granted on April 1, 2026
New grant vesting date
April 1, 2027
End of one-year vesting period for 7,895 Restricted Shares
Restricted Shares vested
8,069 shares
Previously granted Restricted Shares vesting period ending April 1, 2026
Common Stock after conversion
8,069 shares
Common Stock held directly following derivative exercise
Exercise/Conversion price
$0.00 per share
Reported transaction price for Restricted Shares exercise
Derivative exercises in filing
1 exercise, 8,069 shares
transactionSummary exerciseCount and exerciseShares
Key Terms
Restricted Shares, derivative security, Treasury Regulation 1.409A-2, deferral election, +1 more
5 terms
derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
Treasury Regulation 1.409A-2 financial
"subject to a deferral election by the Reporting Person in accordance with Treasury Regulation 1.409A-2"
deferral election financial
"Such shares remain subject to a deferral election by the Reporting Person"
vesting period financial
"will vest, without performance criteria, at the end of a one-year vesting period"
A vesting period is the set amount of time someone must wait before they fully own granted shares, stock options, or other equity tied to their work or an agreement; ownership increases gradually or in steps during that time. Investors care because vesting determines when insiders or employees can sell shares, which affects future supply of stock, company incentives and executive retention—think of it like unlocking ownership over installments rather than receiving it all at once.
FAQ
What did Core Laboratories (CLB) director Robert F. Martinovich report in this Form 4?
Robert F. Martinovich reported equity compensation activity, not market trades. He received a grant of 7,895 Restricted Shares and saw 8,069 previously granted Restricted Shares vest and convert into 8,069 shares of Common Stock, which he now holds directly.
Does this Core Laboratories (CLB) Form 4 show any open-market stock purchases or sales?
No, the Form 4 reports only equity award grants and the vesting and conversion of Restricted Shares into Common Stock. The transactions use codes A and M, indicating awards and derivative exercises, with no open-market buy or sell transactions disclosed in this filing.